181 related articles for article (PubMed ID: 30412596)
41. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
42. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
Murray A; Lourenco T; de Verteuil R; Hernandez R; Fraser C; McKinley A; Krukowski Z; Vale L; Grant A
Health Technol Assess; 2006 Nov; 10(45):1-141, iii-iv. PubMed ID: 17083853
[TBL] [Abstract][Full Text] [Related]
43. Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.
Chowdhury EK; Ademi Z; Moss JR; Wing LMH; Reid CM;
Medicine (Baltimore); 2015 Mar; 94(9):e590. PubMed ID: 25738481
[TBL] [Abstract][Full Text] [Related]
44. Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model.
Chan HY; Wijnen BFM; Majoie MHJM; Evers SMAA; Hiligsmann M
Epilepsia; 2022 Mar; 63(3):641-651. PubMed ID: 34967942
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
Salcedo J; Bulovic J; Young CM
Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
[TBL] [Abstract][Full Text] [Related]
46. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
47. Is brief advice in primary care a cost-effective way to promote physical activity?
Anokye NK; Lord J; Fox-Rushby J
Br J Sports Med; 2014 Feb; 48(3):202-6. PubMed ID: 24352807
[TBL] [Abstract][Full Text] [Related]
48. Short-term and long-term cost-effectiveness of a pedometer-based exercise intervention in primary care: a within-trial analysis and beyond-trial modelling.
Anokye N; Fox-Rushby J; Sanghera S; Cook DG; Limb E; Furness C; Kerry SM; Victor CR; Iliffe S; Ussher M; Whincup PH; Ekelund U; deWilde S; Harris T
BMJ Open; 2018 Oct; 8(10):e021978. PubMed ID: 30337309
[TBL] [Abstract][Full Text] [Related]
49. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina.
Zhang Y; Yin L; Mills K; Chen J; He J; Palacios A; Riviere AP; Irazola V; Augustovski F; Shi L
JAMA Netw Open; 2021 Sep; 4(9):e2122559. PubMed ID: 34519769
[TBL] [Abstract][Full Text] [Related]
51. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
53. Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.
Gao L; Moodie M
Int J Behav Nutr Phys Act; 2022 Dec; 19(1):152. PubMed ID: 36517831
[TBL] [Abstract][Full Text] [Related]
54. Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(15):1-167. PubMed ID: 29213344
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas.
Wang H; Kenkel D; Graham ML; Paul LC; Folta SC; Nelson ME; Strogatz D; Seguin RA
BMC Health Serv Res; 2019 May; 19(1):315. PubMed ID: 31096977
[TBL] [Abstract][Full Text] [Related]
59. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of a domestic violence and abuse training and support programme in primary care in the real world: updated modelling based on an MRC phase IV observational pragmatic implementation study.
Barbosa EC; Verhoef TI; Morris S; Solmi F; Johnson M; Sohal A; El-Shogri F; Dowrick S; Ronalds C; Griffiths C; Eldridge S; Lewis NV; Devine A; Spencer A; Feder G
BMJ Open; 2018 Aug; 8(8):e021256. PubMed ID: 30158224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
